
Ed Smylie, Who Saved the Apollo 13 Crew With Duct Tape, Dies at 95
Robert 'Ed' Smylie, the NASA official who led a team of engineers that cobbled together an apparatus made of cardboard, plastic bags and duct tape that saved the Apollo 13 crew in 1970 after an explosion crippled the spacecraft as it sped toward the moon, died on April 21 in Crossville, Tenn. He was 95.
His death, in a hospice facility, was confirmed by his son, Steven.
The day after the astronauts Jim Lovell, Jack Swigert and Fred Haise returned to earth on April 17, 1970, President Richard M. Nixon awarded NASA's mission operations team with the Presidential Medal of Freedom. In his remarks, he singled out Mr. Smylie and his deputy, James V. Correale.
'They are men whose names simply represent the whole team,' President Nixon said at a ceremony at the Manned Spacecraft Center in Houston. 'And they had a jerry-built operation which worked, and had that not occurred, these men would not have gotten back.'
Soft-spoken, with an accent that revealed his Mississippi upbringing, Mr. Smylie was relaxing at home in Houston on the evening of April 13 when Mr. Lovell radioed mission control with his famous (and frequently misquoted) line: 'Uh, Houston, we've had a problem.'
An oxygen tank had exploded, crippling the spacecraft's command module.
Mr. Smylie, who lived five houses down from Mr. Haise, saw the news on television and called the crew systems office, according to the 1994 book 'Lost Moon' by Mr. Lovell and the journalist Jeffrey Kluger. The desk operator said the astronauts were retreating to the lunar excursion module, which was supposed to shuttle two crew members to the moon.
'I'm coming in,' Mr. Smylie said.
Mr. Smylie knew there was a problem with this plan: The lunar module was equipped to safely handle air flow for only two astronauts. Three humans would generate lethal levels of carbon dioxide.
To survive, the astronauts would need to somehow refresh the canisters of lithium hydroxide that would absorb the poisonous gases in the lunar excursion module. There were extra canisters in the command module, but they were square; the lunar module ones were round.
'You can't put a square peg in a round hole, and that's what we had,' Mr. Smylie said in the documentary 'XIII' (2021).
He and about 60 other engineers had less than two days to invent a solution using materials already onboard the spacecraft. The crisis is depicted in Ron Howard's 1995 blockbuster film, 'Apollo 13,' starring Tom Hanks as Mr. Lovell, Kevin Bacon as Mr. Swigert and Bill Paxton as Mr. Haise.
Onscreen, a character inspired by Mr. Smylie dramatically dumps rubber tubes, garment bags, duct tape and other materials onto a table. 'The people upstairs handed us this one,' the character says, 'and we gotta come through.'
In reality, the engineers printed a supply list of the equipment that was onboard. Their ingenious solution: an adapter made of two lithium hydroxide canisters from the command module, plastic bags used for garments, cardboard from the cover of the flight plan, a spacesuit hose and a roll of gray duct tape.
'If you're a Southern boy, if it moves and it's not supposed to, you use duct tape,' Mr. Smylie said in the documentary. 'That's where we were. We had duct tape, and we had to tape it in a way that we could hook the environmental control system hose to the command module canister.'
Mission control commanders provided step-by-step instructions to the astronauts for locating materials and building the adapter. In between steps, they joked about taxes. (It was, after all, April.)
'OK, Jack,' one of the commanders radioed. 'Did anybody ever tell you that you got a 60-day extension on your income tax? Over.'
'Yes,' Mr. Swigert replied. 'I think somebody said that when you are out of your country, you get a 60-day extension.'
The adapter worked. The astronauts were able to breathe safely in the lunar module for two days as they awaited the appropriate trajectory to fly the hobbled command module home. They landed in the Pacific Ocean with plenty of time to file their taxes (thanks to the extension).
'We would have died had their solution not worked,' Mr. Haise said in an interview. 'I don't know what more you can say about that.'
Robert Edwin Smylie, known as Ed, was born on Dec. 25, 1929, in Lincoln County, Miss., on his grandfather's farm. His father, Robert Torrey Smylie, delivered ice and later managed an ice-making facility. His mother, Leona (White) Smylie, oversaw the home.
After serving in the U.S. Navy, Mr. Smylie studied mechanical engineering at Mississippi State University, earning a bachelor's degree in 1952 and a master's in 1956. He pursued a doctorate at the University of California, Los Angeles, but didn't finish.
In 1962, he was working at the Douglas Aircraft Company in California when President John F. Kennedy announced plans to send astronauts to the moon.
'I was a young engineer and just wanted to be there and help make it happen,' Mr. Smylie said in a NASA oral history.
He applied for a job at the space agency in Houston, initially working in the environmental control section. He eventually became chief of the crew systems division, which was responsible for the life-sustaining equipment used by Apollo astronauts in space.
Mr. Smylie always played down his ingenuity and his role in saving the Apollo 13 crew.
'It was pretty straightforward, even though we got a lot of publicity for it and Nixon even mentioned our names,' he said in the oral history. 'I said a mechanical engineering sophomore in college could have come up with it.'
Mr. Smylie's marriage to June Reeves in 1954 ended in divorce. He married Carolyn Hall in 1983; she died in 2024.
In addition to Steven, his son, he is survived by his daughters, Susan Smylie and Lisa Willis; his stepchildren, Natalie and Andrew Hall; 12 grandchildren; and 15 great-grandchildren.
Mr. Smylie's lifesaving invention was a seminal moment in the storied history of duct tape, the jack-of-all trades tool kit item.
'Duct tape has come to enjoy a kind of heroic and ever more pervasive presence in American life,' Tisha Y. Hooks observed in 'Duct Tape and the U.S. Social Imagination,' the dissertation she wrote at Yale University in 2015.
'From the Apollo 13 mission to the broken basement pipe,' she wrote, 'duct tape is there.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
14 minutes ago
- Washington Post
Driver stuck after going down Spanish Steps in Rome
We and our third-party partners process personal data including through the use of cookies, pixels, and other tracking technologies to provide, analyze, and improve our services; personalize your experience (including content); and personalize ads on and off the services. Learn more and manage your preferences at our Privacy Policy
Yahoo
19 minutes ago
- Yahoo
The Dumbest Phone Is Parenting Genius
The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here. When Caron Morse's 9-year-old daughter asked for a smartphone last year, her reaction, she told me, was unambiguous: 'A hard hell no.' Morse is a mental-health provider in the Portland, Maine, public-school system, and she was firmly against smartphones, having seen how social media and abundant screen time could shorten students' attention spans and give them new anxieties. But she wanted her children to have some independence—to be able to call friends, arrange playdates, and reach out to their grandparents on their own. She also needed a break. 'I was so sick,' she said, 'of being the middle person in any correspondence.' So when her daughter turned 10, Morse did get her a phone: a landline. For that gift to provide all the benefits she wanted, Morse had to lay some groundwork. It would be annoying if her daughters—she also has an 8-year-old—were to start calling their friends' parents' smartphones all the time, so she told her neighbors about her plan and suggested that they consider getting landlines too. Several bought in immediately, excited for the opportunity to placate their own smartphone-eager kids. And over the next couple of months, Morse kept nudging people. She appealed to their sense of nostalgia by sharing photos of her older daughter sitting on the floor and twirling the landline's cord around her fingers. She wrote messages: 'Guys, this is adorable and working and important.' The peer pressure paid off. Now about 15 to 20 families in their South Portland neighborhood have installed a landline. They've created a retro bubble in which their children can easily call their friends without bugging a parent to borrow their phone—and in which the parents, for now, can live blissfully free of anxieties about the downsides of smartphones. In the past few years, interest in old-school technology has been rising, driven partly by desperate adults seeking smartphone alternatives for their kids. Fairs peddle 'dumb phones' to parents of tweens. On Reddit, one parent shared that they'd gone 'full '90s,' with a desktop computer installed in the living room, a Nintendo 64, and a landline. In March, after a Millennial mom posted on Instagram about getting a home phone for her kids, she received scores of comments from parents saying they'd done the same—or planned to soon. [Read: End the phone-based childhood now] But these are isolated examples. As Jonathan Haidt, the author of The Anxious Generation (which helped inspire Morse's landline purchase), told me, smartphones are so dominant in part because families are beset by a 'collective-action problem.' Many parents are concerned about how their children might use smartphones, and particularly social media. They're familiar with the research suggesting a correlation between social-media use and high rates of anxiety and depression among teens and especially teen girls. Still, parents can struggle to say no to a child asking for a phone when everyone at their school already has one. 'If your child is the only one who is kept away from phones or social media,' Haidt said, 'then you are isolating them.' That's why he encourages parents to band together to reset common norms: 'If you do it with a group, then you're actually fostering more real-world interaction.' When the South Portland landline pod formed, that's exactly what the parents started to see. The phone Morse got her daughter is light pink with a curly cord and sits atop a buffet table outside the family's kitchen. Morse wanted the phone to be in a 'centralized' part of the house, with a cord, so that her daughters couldn't whisk it off to their bedrooms for private conversations or take it with them while they played. 'Very rarely do we ask kids to be still and communicate,' she explained. 'I didn't want my kids to go play with slime when they're on the phone. Communication should be something you're actually focusing on.' Not all of the parents in her pod got corded phones. But everyone I spoke with told me that the devices, corded or not, had helped their children become better listeners and more empathetic communicators. At first, the kids took some time to adjust. Erin Masterson, whose children attend school with Morse's, recalled a time when her 10-year-old son shouted into the phone to a friend, 'ARE YOU HOME?!' And all of the children have had to practice greeting callers, identifying themselves when they place a call, and sometimes asking to speak to someone else. But after a few months, they grew more comfortable. Because audio-only calls tend to come with fewer distractions—no faces to look at, no enticing filters or emoji—Masterson sees her sons 'really tune in to what people are saying.' Mindy Hull, another parent in the neighborhood, has noticed a similar pattern with her 8-year-old daughter. 'The progression from January until now' in the way her daughter 'can engage people in conversation is mind-blowing,' Hull told me. 'She's practicing listening,' and better understands the meaning in subtle verbal cues. Since the landline pod started, the kids have been arranging their own playdates (although they still have to ask their parents for permission). And when an in-person hang isn't possible, they've still been able to connect. Parents told me their children had called friends to ask questions about Dungeons & Dragons, to check on a friend after they were out sick from school, or just to chat on rainy days—all without their parents having to worry about what else the kids might be doing on the phone. The landlines have also given these parents a glimpse into their kids' social lives that they might not otherwise have enjoyed. Recently, Hull listened as her daughter, who uses their phone at least once a day, talked with a friend for an hour and a half. 'They were giggling and laughing and telling stories,' she said. 'I couldn't believe it.' [Read: How the loss of the landline is changing family life] Crucially, parents in the landline pod aren't just banning smartphones; they're giving their children an alternative—a method that's much more likely to make kids happy, Jacqueline Nesi, a psychologist who studies the effects of technology and social media on adolescents, told me. She recommends that parents simply ask their children why they want a smartphone: 'Do they want to be able to communicate with friends? Do they want to play a certain game? Think about what the goals are and then work from there.' The landline solution isn't perfect. Morse told me that when the house phone rings while they're watching a movie, it can be annoying; you can't silence a landline as easily as you can a smartphone. Occasionally, the phone makes a buzzing sound; her daughters have learned to smack it against the table—once, hard—to make it stop. And most of the parents I spoke with acknowledged that, eventually, they would probably get their children a smartphone; they were just trying to postpone that development as long as possible. (Hull is the one holdout I spoke with who thinks her daughter might never need a smartphone while under her roof.) For now, Morse and Masterson are considering limited-function smartwatches as their eldest children head to middle school and begin venturing out more on their own. Masterson wants to get her son a device with only call and text capabilities, so he can arrange rides and activities after school. Morse likes the idea of getting a watch that also has GPS, so she can track her daughter's location. When the time does come for a smartphone—if it comes—the parents hope their children will be better prepared to handle one responsibly. They'll be older and more emotionally mature, and will have passed the age at which experts say a child's brain is particularly vulnerable to the addictive qualities of smartphones. They'll also have communication skills, honed by landline, that could come in handy. After years of practice, they might be quicker to call someone instead of sending a text or leaving a social-media comment, leading to a potentially stronger connection with that person. After all, a smartphone's most basic feature—and, I would argue, its best—is one it shares with a landline: the ability to call a friend and talk. When you buy a book using a link on this page, we receive a commission. Thank you for supporting The Atlantic. Article originally published at The Atlantic
Yahoo
an hour ago
- Yahoo
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company'), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub ('HTH') Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute ('ARMI') and its BioFabUSA initiative. NurExone's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market following the establishment of Exo-top Inc. ('Exo-TOP'), the Company's wholly owned U.S. subsidiary dedicated to GMP-compliant exosome manufacturing for clinical development and commercial scale-up. HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel's Ministry of Health. The HTH Accelerator Program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies, and build meaningful collaborations with key stakeholders across the U.S. HealthTech landscape. The program is funded by HTH at no cost to participants. Dr. Lior Shaltiel, CEO of NurExone, commented: 'The HTH Acceleration Program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-TOP to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world's largest healthcare market 2.' NurExone's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs. Omnibus Plan Approval The Company is pleased to announce that, further to its press release dated June 4, 2025, at the Company's annual general and special meeting held on June 18, 2025 (the 'Meeting'), disinterested shareholders ratified and approved the amended and restated omnibus incentive plan (the 'Omnibus Plan'), a copy of which is available under the Company's SEDAR+ profile at The Omnibus Plan is a hybrid plan that provides flexibility to grant-equity incentive awards in the form of stock options ('Options'), restricted shares ('Restricted Shares') and restricted share units ('RSUs'). The Omnibus Plan is a hybrid 10% rolling and 10% fixed share-based compensation plan that amends and restates the Company's previous equity incentive plan approved by shareholders on June 4, 2024 (the 'Previous Plan'). The Previous Plan was a 20% fixed share-based compensation plan whereby the maximum number of common shares in the capital of the Company ('Common Shares') reserved for issuance was set at 13,166,085, representing 20% of the issued and outstanding Common Shares as of the effective date. The Omnibus Plan now includes (i) a 10% 'rolling' Option component that shall not exceed 10% of the Company's total issued and outstanding Common Shares from time to time; and (ii) a 10% fixed component permitting up to 7,800,781 RSUs and Restricted Shares in the aggregate. Additionally, the Omnibus Plan was amended to increase the number of securities issuable to insiders of the Company. The Previous Plan provided, that unless approved by disinterested shareholders, (i) the maximum number of securities issuable to insiders collectively would not exceed 10% of the Company's securities at any time and (ii) the maximum number of securities issuable to insiders collectively in any twelve-month period would not exceed 10% of the Company's total issued and outstanding securities as at the date any award was granted to an insider. Now, the Omnibus Plan provides the following that (i) the maximum number of the Company's securities issuable to insiders collectively shall not exceed 20% of the Company's total issued and outstanding Common Shares at any point in time and (ii) the maximum number of the Company's securities issuable to insiders collectively, in any 12-month period, when combined with all of the Company's other share compensation arrangements, shall not exceed 20% of the Company's total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider. RSU Grants In addition, the Company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the Company pursuant to the terms and conditions of the Omnibus Plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one Common Share. The RSUs and underlying Common Shares are subject to the Exchange Hold Period (as such term is defined under the policies of the TSX Venture Exchange ('TSXV')). About NurExone NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy. For additional information and a brief interview, please watch Who is NurExone?, visit or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: info@ Dr. Eva ReuterInvestor Relations – GermanyPhone: +49-69-1532-5857Email: Allele Capital PartnersInvestor Relations – +1 978-857-5075Email: aeriksen@ press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the; the Company's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company's acceptance into the prestigious HTH Accelerator Program will allow it to support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will give the Company the ability to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company's inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not engage with regulatory agencies; the Company's acceptance into the prestigious HTH Accelerator Program will not support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will not enhance its visibility within the U.S. regenerative medicine ecosystem and will not support its mission as discussed herein; each RSU will not be settled into one Common Share; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's Annual Information Form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. i Spinal cord injury, Glaucoma 1